Contents lists available at [ScienceDirect](http://www.sciencedirect.com/science/journal/03009572)

# Resuscitation

j ourna l ho me pa g e: [www.elsevier.com/locate/resuscitation](http://www.elsevier.com/locate/resuscitation)


#### Clinical Paper

## High cumulative oxygen levels are associated with improved survival of children treated with mild therapeutic hypothermia after cardiac
 arrest[�][,][��]

### Lennart van Zellem [a], Rogier de Jonge [b], Joost van Rosmalen [c], Irwin Reiss [b], Dick Tibboel [a], Corinne Buysse [a][,][∗]

a Erasmus MC – Sophia Children’s Hospital, Intensive Care and Department of Pediatric Surgery, Rotterdam, The Netherlands
b Erasmus MC – Sophia Children’s Hospital, Department of Neonatology, Rotterdam, The Netherlands
c Erasmus MC, Department of Biostatistics, Rotterdam, The Netherlands


##### a r t i c l e i n f o

Article history:
Received 8 August 2014

Received in revised form

21 November 2014

Accepted 19 December 2014


##### a b s t r a c t

Aim: The aim of this study was to analyze the relationship between the partial pressure of arterial oxygen
(PaO2) and in-hospital (IH) mortality in children after cardiac arrest (CA) using the conventional cutoff

analysis, which was compared with the cumulative analysis, a new method in PaO2 analysis. Additionally, we analyzed this relationship for children with and without mild therapeutic hypothermia (MTH;

32–34 [◦]C).
Methods: This observational cohort study included all children (aged >28 days) with CA and return of

spontaneous circulation (ROSC) between 2002 and 2011.
The first research question was the association between PaO2 and IH mortality after ROSC. This was ana
lyzed for three hyperoxia cutoff values, and for three time intervals using the cumulative PaO2 determined
with the area under the curve (AUC). For the second research question, these analyses were repeated for

children with and without MTH.
Results: Of the 200 patients included (median age 2.6 years), 84 (42%) survived to hospital discharge.

Fifty-eight children (29%) were treated with MTH.
With the cutoff analysis and the AUC analysis we found no relationship between PaO2 and IH mortality.

However, analysis of the MTH-group showed a lower IH mortality in children with high cumulative PaO2
levels on two of the three time intervals. Multivariable analysis showed significantly higher odds of

survival (0.643 (95% confidence interval (CI) 0.424–0.976), 0.554 (95%CI 0.335–0.916)).
Conclusions: Cumulative PaO2 analysis showed that the IH mortality is significantly lower in MTH-treated

children with high PaO2 levels. The effects of cumulative PaO2 on the outcome need to be studied further,

and this will help us to achieve individualized goal-directed therapy.

© 2015 Elsevier Ireland Ltd. All rights reserved.


Keywords:
Hyperoxia
Heart arrest

Area under curve

Hypothermia
Induced
Pediatrics


Abbreviations: APLS, advanced pediatric life support; AUC, area under the
curve; BLS, basic life support; CA, cardiac arrest; CI, confidence interval; OH, out
of-hospital; IH, in-hospital; MTH, mild therapeutic hypothermia; NICU, neonatal

intensive care unit; OR, odds ratio; PaO2, partial pressure of arterial oxygen; ICU,

intensive care unit; ROSC, return of spontaneous circulation; SIRS, systemic inflam
matory response syndrome.

� A Spanish translated version of the abstract of this article appears as Appendix
in the final online version at [http://dx.doi.org/10.1016/j.resuscitation.2014.12.013.](http://dx.doi.org/10.1016/j.resuscitation.2014.12.013)

�� Performed at: Erasmus MC – Sophia Children’s Hospital, Rotterdam, The

Netherlands.
∗ Corresponding author at: Erasmus MC – Sophia Children’s Hospital, Intensive

Care and Department of Pediatric Surgery, Wytemaweg 80, 3015 CN Rotterdam, The

Netherlands.
E-mail address: [c.buysse@erasmusmc.nl](mailto:c.buysse@erasmusmc.nl) (C. Buysse).

http://dx.doi.org/10.1016/j.resuscitation.2014.12.013
0300-9572/© 2015 Elsevier Ireland Ltd. All rights reserved.


**1.** **Introduction**

Cardiac arrest (CA) in children is uncommon and associated
with high mortality (50–90%).[1–6] Oxygen therapy has always been
important in the treatment of CA. However, there is increasing

evidence for the adverse effects of oxygen. Oxidative stress and
reperfusion promote free radical-generated injury contributing
to neurologic injury and cardiac dysfunction, and they seem to
be associated with increased mortality after CA.[7,8] Furthermore,

a meta-analysis of animal studies by Pilcher et al. showed that
treatment with 100% oxygen after resuscitation resulted in significantly worse neurological deficit scores than oxygen administered
at lower concentrations.[9]

Observational studies in humans examined the influence of
arterial oxygen (PaO2) on in-hospital (IH) mortality. They used


-----

different time intervals after return of spontaneous circulation
(ROSC) and different definitions of hyperoxia, or included only
patients treated with mild therapeutic hypothermia (MTH), which
resulted in contradictory conclusions.[10–16] Most studies used an
arbitrary cutoff value to describe the influence of PaO2 on the
IH mortality. Only two studies used an alternative method. Janz
et al. used PaO2 as a continuous value and Ferguson et al. modeled
the first PaO2 within the first hour after ROSC in a non-linear
matter.[11,13]

In contrast with previous studies, we hypothesized that not a
single value above a previously set cutoff, but rather the cumulative
PaO2 during the first 24 h after ROSC (especially the first 6 h) is associated with worse survival of children with CA. Our first research
question was the association between PaO2 and the IH mortality,
analyzed with the commonly used cutoff method and compared
with a cumulative method. In addition, although the evidence for
the protective effects of MTH is debatable, we hypothesized that
MTH is protective against the effects of hyperoxia, as it is the only
post-resuscitation intervention, introduced in our hospital in 2007,
in accordance with international guidelines.

**2.** **Methods**

This observational cross-sectional cohort study was performed
at the intensive care unit (ICU) of the Erasmus MC – Sophia
Children’s Hospital, a tertiary-care university hospital. Our hos
pital provides health care to children in the southwest of The
Netherlands (total population of approximately 4.2 million people), and this population is a representative sample of the Dutch
population.

2.1. Patient selection

This study concerned all patients aged >28 days and <18 years
with documented CA between January 2002 and December 2011,
and admitted to the ICU of the Erasmus MC – Sophia Children’s
Hospital. CA was defined as absent pulse rate or the need for cardiac
compressions. Treatment of children with CA in our hospital has
been in line with the European Resuscitation Council guidelines for
pediatric life support.[17]

The inclusion criteria were as follows: (1) all children resuscitated in-hospital (e.g. emergency department, ward, or ICU) and
out-of-hospital, and consecutively admitted to our ICU, and (2)
children resuscitated in a regional hospital or other university hospital, and after ROSC consecutively admitted to our ICU. Neonatal
resuscitations, children with cyanotic congenital heart disease, and
children without an arterial line were excluded. In addition, only
data of the first CA episode were included when a child had multiple
arrests.
Hypothermia was introduced as treatment after CA in children
with post-resuscitation coma in 2007. Hypothermia was started
as soon as possible following ROSC. Hypothermia was achieved by
administering a bolus of cold fluids and applying external cooling
using a mattress with Blanketrol[®] III (Cincinnati Sub-Zero Products,
Inc., Sharonville, OH, USA). The target temperature is 32–34 [◦]C for
24 h following ROSC, after which they were rewarmed passively

at a rate of 0.5 [◦]C per 2 h. The target temperature must have been
reached for MTH to be effective. Children in whom the target temperature range was not reached were classified as “without MTH”.

2.2. Data collection

All CA data were retrospectively collected. CA data were derived
from ambulance registration forms, clinical medical records, electronic medical records, Patient Data Management System (PDMS),
and CA registration forms. The starting point of the time interval of


collected data (T = 0) was defined as the actual time of ROSC or, if
unknown, the time of ICU admission.
The following data were collected: (1) basic patient characteristics (e.g., gender, age, and medical history), (2) CA characteristics
(e.g., type of resuscitation (basic life support (BLS)/advanced pediatric life support (APLS)), etiology of arrest, first monitored rhythm,
bystander cardiopulmonary resuscitation (CPR), and location), and
(3) outcome (IH mortality).
For all children, laboratory values (arterial pH, lactate, and
PaO2) and data regarding MTH (time period before MTH reached,
lowest temperature if >34 [◦]C) were retrospectively collected. The
laboratory values of all children were automatically recalculated
to the value at 37 [◦]C, as this is a standard procedure in our
hospital.[18]

2.3. Statistical analysis

The primary outcome measure was IH mortality. The first
research question was the association between PaO2 and IH mor
tality. The second question was the influence of MTH on this
association.
In the first analysis of the first research question, we explored
the association between PaO2 and IH mortality for different cut
off values of hyperoxia (>200, >250 and >300 mmHg) as proposed
in the literature.[13–16] Logistic regression analysis was applied to
explore the influence of hyperoxia on IH mortality with the highest
PaO2 over the first 24 h. In the multivariable analysis, we calculated
an adjusted odds ratio (OR) for pre-selected variables: age, gender,
type of resuscitation (BLS/APLS), location, rhythm, lowest pH and
highest lactate.
In the second analysis of the first research question, the “area
under the curve” (AUC) of PaO2 was calculated for each patient to
determine the influence of the cumulative PaO2 on IH mortality.
The trapezoidal method was used. A minimum of four PaO2 measurements and an overall time interval of at least 12 h were required
to include the arterial measurements and their corresponding time
points in the analysis. This resulted in a cumulative PaO2 over the
0–6 h, 6–24 h, and 0–24 h interval after ROSC. The AUC was corrected for the time in which the PaO2 was measured, as not all
patients had a 24 h time period in which PaO2 was measured. This
resulted in a cumulative PaO2 per hour, which was converted into
the cumulative PaO2 by multiplying with 6, 18, or 24, respectively.
In univariable logistic regression analyses, the assumption that
the AUC of PaO2 had a linear effect on the logit of IH mortality was
tested using the Box–Tidwell test (i.e., an interaction term between
the covariate and its natural logarithm was added to the model).
If any significant interaction between the covariate and its natural logarithm was present, the linearity assumption was violated.
Univariable and multivariable logistic regression analysis (with the
same preselected variables as in the cutoff analysis) was applied to
evaluate the relationship between cumulative PaO2 and IH mortality over the three time intervals after ROSC. In advance of the
regression analysis, the original AUC variables were rescaled by
dividing by 100 to obtain more distinctive results out of the logistic
regression analysis.
The same analyses were performed regarding the influence of
MTH on the association between PaO2 and IH mortality.
Univariable comparison of the distribution of patient characteristics and clinical data between survivors and non-survivors was
performed by independent sample t-tests for normally distributed
data, and Mann–Whitney U tests for non-normally distributed
data. Normality was examined with the Kolmogorov–Smirnov test.
Fisher’s exact test was used for comparison of dichotomous data.
Statistical significance was considered with two-tailed p-value of

≤0.05.


-----

**Fig.** **1.** Overview of the patient inclusion.

All analyses were performed with SPSS 21.0 for Windows (SPSS,
Inc., Chicago, IL, USA) or GraphPad Prism 5.00 for Windows (GraphPad Software, Inc.).

**3.** **Results**

3.1. Patient and CA characteristics

Between January 2002 and December 2011, a total of 474 CA
events were documented. ROSC was achieved in 335 events (70%).

An overview of the patient inclusion is given in Fig. 1. The basic
patient characteristics are presented in Table 1.
MTH was initiated in 63 (32%) children, 58 (92%) of whom
reached the target temperature in a median time of 6.7 h (range:
0.8–21.3) for survivors and 6.3 h (range: 0.4–25.5) for non-survivors
after ROSC.
Eventually, 116 of the 200 children (58%) died within a median
of 2 days (range: 0–135; 40 died within the first 24 h) after ROSC.
The major cause of death was withdrawal of life-sustaining treatment (poor physical and/or (neuro)psychological outcome based
on repeated neurological examination, brain imaging, and electroencephalography) (n = 52, 45%), followed by brain death based
on the criteria of whole-brain death (n = 31, 27%), cardiorespiratory
failure/multiple-organ failure (n = 31, 27%), and underlying disease
(n = 2, 2%).

3.2. PaO2 cutoff analysis

All 200 patients were included in the cutoff analysis. No significant difference between survivors and non-survivors was found
(Table 1).
The influence of the highest measured PaO2 on the overall mortality is presented in Table 2.
Table 3 displays the influence of PaO2 on IH mortality for
patients with and without MTH. The univariable analysis of

maximum PaO2 values >250 mmHg showed a significantly lower


survival rate of children without MTH treatment, which was no
longer present in the multivariable analysis.

3.3. Cumulative PaO2 analysis

Forty-eight children (24%) were excluded from the AUC calculation (less than four measurements and/or time interval <12 h)
(Table 1).
The results of the Box–Tidwell tests showed no significant nonlinear effects of the AUC of PaO2 on the logit of IH mortality.
Univariable and multivariable regression analyses showed no
significant relationship between the cumulative AUC of PaO2 and
IH mortality (Table 2).
Multivariable regression analysis, evaluating the relationship
between cumulative PaO2 and IH mortality for patients with and
without MTH, showed an overall significant difference (OR 0.916,

95% CI 0.843–0.995; p = 0.038) toward a lower risk of mortality over
the 0–24 h interval in patients with MTH. This was also found on the
6–24 h interval (OR 0.882, 95% CI 0.792–0.981; p = 0.021) in patients
with MTH (Fig. 2).

3.3.1. Clinical relevance
As shown by five examples (Fig. 3), both methods led to substan
tially different results. As to the cumulative PaO2 in patients with
MTH, the mean AUC of survivors with MTH was 502.7 points higher
over the 0–24 h interval, and 469.9 points higher over the 6–24 h
interval, than that of non-survivors. As the AUC was rescaled before

being entered in the regression analysis, the mean difference had
to be rescaled by dividing by 100. Ultimately, this resulted in a clinically relevant difference in OR of 0.643 (95% CI 0.424–0.976) and
0.554 (95% CI 0.335–0.916). The odds of survival are significantly
increased in children with higher cumulative PaO2 levels over the
6–24 h and 0–24 h interval.


**4.** **Discussion**

The innovative aspect of this study is that it uses a novel and
simple method to analyze cumulative PaO2. We found that patients

with MTH and higher cumulative PaO2 had a lower mortality rate.
With the cumulative PaO2 measurement, we could not reproduce
the relationship between higher PaO2 and IH mortality in children
after CA as found in various cutoff studies. It is important to note
that, due to the retrospective nature, small sample size, and heterogeneous population, we did not determine causation in this study,
this study is hypothesis generating.

4.1. Patient and CA characteristics


The patient sample was heterogeneous in terms of location and
etiologies, among other things, which was also the case in other

studies.[10,11,13,15] Half of the CAs were out-of-hospital CAs, the proportion of which was within the range reported in other studies
(from 43% to 58%).[12,13,16] In our population, out-of-hospital CA was
also more common (70%) in patients with MTH.

Only 32% underwent MTH after CA, because MTH was newly
introduced in our clinical protocol in 2007 and it was only used in
children with post-resuscitative coma after CPR. Similar to other
studies our median time to reach the MTH target temperature

was >6 h, most probably due to unfamiliarity with the new protocol and failure of the technique.[19,20] The exact timing to start
hypothermia after ROSC is controversial, as well as the duration and
temperature.[21–23] There could be a therapeutic window in which
hypothermia should be applied.[21,23] Furthermore, controlling the

effects of systemic inflammatory response syndrome (SIRS) with
continued normothermia could be important.[22]


-----

**Table** **1**
Patient characteristics and cardiac arrest characteristics.

Survivors (n = 84) Non-survivors (n = 116) p-Value[d]

n[a] n[a]

Age (months)[b] 84 20.4 (1.0–211.9) 116 37.6 (1.0–262.6) 0.069
Male gender[c] 84 49 (58%) 116 61 (53%) 0.472

Advanced pediatric life support (APLS)[c] 84 64 (76%) 116 107 (92%) 0.002

Out-of-hospital arrest[c] 84 37 (44%) 116 61 (53%) 0.254

Bystander CPR[c] 79 74 (88%) 112 93 (80%) 0.044

Initial rhythm non-shockable[c] 77 64 (76%) 107 99 (85%) 0.060

Etiology 84 116

-Cardiac[c] 27 (32%) 33 (39%) 0.640
-Arrhythmia[c] 27 8 (30%) 33 3 (9%)
-Cardiomyopathy[c] 27 8 (30%) 33 8 (24%)
-Hypovolemic shock[c] 27 1 (4%) 33 5 (15%)
-Obstructive shock[c] 27 2 (7%) 33 2 (6%)

-Septic shock[c] 27 6 (22%) 33 14 (42%)

-Other[c] 27 2 (7%) 33 1 (3%)
-Respiratory[c] 49 (58%) 46 (40%) 0.010
-Aspiration[c] 49 1 (2%) 46 6 (13%)
-Bronchomalacia/spasm[c] 49 4 (8%) 46 1 (2%)
-Congenital[c] 49 3 (6%) 46 3 (7%)
-Drowning[c] 49 19 (39%) 46 12 (26%)

-Hanging[c] 49 2 (4%) 46 2 (4%)
-Insufficiency/infection[c] 49 8 (16%) 46 11 (24%)
-Obstruction other[c] 49 9 (18%) 46 3 (7%)

-Pulmonary hypertension[c] 49 2 (4%) 46 1 (2%)

-Other[c] 49 1 (2%) 46 7 (15%)
-Neurologic[c] 2 (2%) 26 (22%) <0.001
-Herniation[c] 2 0 (0%) 26 3 (12%)
-Vascular accident[c] 2 0 (0%) 26 3 (12%)

-Trauma[c] 2 0 (0%) 26 18 (69%)
-Other[c] 2 2 (100%) 26 2 (8%)
-ALTE/SIDS[c] 3 (4%) 6 (5%) 0.737
-Other/unkown[c] 3 (4%) 5 (4%) 1.000

Pre-existing condition[c] [,] [e] 83 36 (43%) 114 44 (38%) 0.558
-Cardiac[c] 20 (56%) 23 (52%) 0.824
-Respiratory[c] 13 (36%) 16 (36%) 1.000
-Neurologic[c] 2 (6%) 3 (7%) 1.000
-Other/unkown[c] 1 (3%) 2 (5%) 1.000
Mild therapeutic hypothermia[c] [,] [f] 84 26 (31%) 116 37 (31%) 1.000

   - 32–34 [◦]C reached[c] 26 22 (85%) 37 36 (97%) 0.150

Lowest pH[b] 84 7.18 (6.47–7.53) 116 7.04 (6.36–7.46) <0.001
Highest lactate[b] 83 4.5 (1.1–24.0) 112 12.1 (0.9–25.0) <0.001

Lowest PaO2 [b] 84 66.0 (18.8–171.8) 116 54.8 (12.8–240.0) 0.154

Highest PaO2 [b] 84 229.9 (32.3–624.8) 116 273.4 (27.0–628.6) 0.394

Min. PaO2 < 60 mmHg[c] 84 31 (37%) 116 61 (53%) 0.032

Max. PaO2 > 200 mmHg[c] 84 51 (61%) 116 76 (66%) 0.551

Max. PaO2 > 250 mmHg[c] 84 37 (44%) 116 65 (56%) 0.115

Max. PaO2 > 300 mmHg[c] 84 31 (37%) 116 52 (45%) 0.309
AUC 0–24 h mmHg[b] 69 2966.9 (1271.6–5785.5) 83 3157.2 (565.9–5405.5) 0.585

-mmHg/h 69 123.6 (53.0–241.1) 83 131.5 (23.6–225.2)

AUC 0–6 h mmHg[b] 64 854.0 (297.8–2066.9) 78 870.7 (166.7–2290.2) 0.925

-mmHg/h 64 142.3 (49.6–344.5) 78 145.1 (27.8–381.7)

AUC 6–24 h mmHg[b] 68 2063.0 (930.3–4645.2) 81 2199.6 (424.4–3911.5) 0.424

-mmHg/h 68 114.6 (51.7–258.1) 81 122.2 (23.6–217.3)


Abbreviations: ALTE = apparent life threatening event, AUC = area under the curve, max. = maximum, n = number, PaO2 = partial pressure of arterial oxygen, SIDS = sudden
infant death syndrome.

a Number of subjects in whom the variable was obtained.
b Median (range).
c Number of subjects (%).
d p-Value: independent sample t-test for continuous data or Mann–Whitney U test dependent on normality; Fisher’s exact test for dichotomous data.
e Children with a pre-existing medical history that was the cause of CA, classified by the etiology of the CA.
f Children in whom mild therapeutic hypothermia was initiated (n = 63).


4.2. Method of PaO2 analysis

Most studies on hyperoxia and CA used a single cutoff value to
describe PaO2 over different time periods after ROSC.[10,12,14–16] Such
cutoff analyses may be limited, however, in their ability to approximate the complex oxygen physiology as fluctuations of PaO2 are
common. Using AUC as a measure of cumulative exposure to oxygen, patients with MTH and high cumulative PaO2 levels had a
lower mortality rate, which was not found in the cutoff analyses. In
addition, we did not find any harmful effects of the high cumulative


arterial oxygen levels whatsoever. This supports our hypothesis
that the method of analysis is important in the approximation of
oxygen physiology. A dichotomous cutoff value cannot account for
the amount of oxygen and duration, an inherent problem of summarizing a continuous variable with an important time course as a
dichotomous variable.
We chose to use different time periods in the AUC analysis, as
both direct cell injury after an ischemic event and delayed cell death
known as reperfusion injury have an important influence on the
outcome. Therefore, it is difficult to compare our results with other


-----

**Table** **2**

Univariable and multivariable logistic regression analyses of all children with survival as dependent variable.

Variable Crude Adjusted[a]

OR (95% CI) p-Value OR (95% CI) p-Value


Max. PaO2 > 200 mmHg 1.230 (0.687)–(2.198) 0.813 0.810 (0.413)–(1.590) 0.541
Max. PaO2 > 250 mmHg 1.618 (0.920)–(2.849) 0.095 1.107 (0.581)–(2.114) 0.756

Max. PaO2 > 300 mmHg 1.389 (0.782)–(2.469) 0.262 0.905 (0.465)–(1.761) 0.770

AUC 0–24 h mmHg[b] 0.998 (0.966)–(1.030) 0.894 0.984 (0.949)–(1.021) 0.403

AUC 0–6 h mmHg[b] 0.998 (0.924)–(1.078) 0.957 0.971 (0.892)–(1.057) 0.497

AUC 6–24 h mmHg[b] 0.997 (0.955)–(1.042) 0.903 0.980 (0.933)–(1.031) 0.447

Abbreviations: AUC = area under the curve, max. = maximum, OR = odds ratio, PaO2 = partial pressure of arterial oxygen.

a Adjusted for: age, gender, location of arrest, rhythm, basic life support/advanced pediatric life support, lowest pH, and highest lactate.
b Value was rescaled by dividing by 100 in advance of the regression analysis.


studies, but these different methods extend our knowledge of these
concepts.
The cumulative PaO2 can be legitimately measured with the
trapezoidal AUC method.[24] This method is commonly used in pharmacokinetic research to measure the total drug exposure, and it has
also been used in other medical fields, for instance in metabolic
research and pulmonary research.

4.3. Cumulative PaO2 and outcome

The analysis of patients without MTH showed no significant
relationship between PaO2 and IH mortality, regardless of the
method used. This is similar to findings of Bellomo et al., who found
no significant difference after Cox proportional-hazards modeling
in a large retrospective cohort of 12,108 patients.[10]

In multivariable analysis, clinically relevant differences in OR
were found. There are various explanations for our findings. One
important new theory is that of a therapeutic window for oxygen.


As suggested by Martin et al., precise control of arterial oxygenation
may avoid harmful effects associated with unnecessary extremes
of arterial oxygenation.[25] Based on physiological principles, they

constructed a scheme with an optimal therapeutic oxygenation
range. This optimal range will probably be dependent on factors
such as age, clinical setting, underlying disease, and other comorbidities. In our retrospective cohort, the cumulative oxygen levels
in survivors with MTH were higher than in the non-survivors with
MTH. This suggests that MTH might shift the optimal therapeutic
range wherein high cumulative oxygen levels could be favorable
compared to lower cumulative oxygen levels.

An alternative explanation is the possibility of impairments
in microcirculatory function. As shown by van Genderen et al.
and Buijs et al., macrocirculatory parameters cannot estimate
microcirculatory function and MTH causes abnormalities in microcirculation and peripheral tissue perfusion.[26,27] Buijs et al. found
that the microcirculation was impaired during MTH and more
severely impaired at the start of MTH in non-survivors. Despite


**Fig.** **2.** Cumulative PaO2 of all children with and without MTH treatment. (A) Cumulative PaO2 in children without hypothermia. (B) Cumulative PaO2 in children with
hypothermia. Each boxplot shows a minimum, 25th percentile, median, 75th percentile, and maximum value. The p-values of the multivariable regression analysis are

shown.


-----

**Table** **3**
Univariable and multivariable logistic regression analyses of all children with and without mild therapeutic hypothermia treatment with survival as dependent variable.

Variable Survivors Non-survivors p-Value[d] Crude Adjusted[e]


n[a] n[a] OR (95% CI) p-Value OR (95% CI) p-Value


No hypothermia[g]

Max. PaO2 > 200 mmHg[b] 62 37 (60%) 80 52 (65%) 0.600 1.255 (0.633)–(2.488) 0.516 0.899 (0.394)–(2.053) 0.801
Max. PaO2 > 250 mmHg[b] 62 23 (37%) 80 45 (56%) 0.028 2.179 (1.106)–(4.310) 0.024 1.912 (0.866)–(4.237) 0.109

Max. PaO2 > 300 mmHg[b] 62 19 (31%) 80 35 (44%) 0.120 1.761 (0.876)–(3.534) 0.112 1.166 (0.518)–(2.625) 0.711

AUC 0–24 h mmHg[c] [,] [f] 47 2712.2 (1271.6–5283.4) 48 3295.0 (778.2–5405.5) 0.100 1.025 (0.983)–(1.067) 0.245 1.014 (0.964)–(1.067) 0.576

-mmHg/h[c] 47 113.0 (53.0–220.1) 48 137.3 (32.4–225.2)
AUC 0–6 h mmHg[c] [,] [f] 45 844.6 (399.0–2066.9) 45 874.0 (166.7–2290.2) 0.812 1.006 (0.913)–(1.107) 0.909 0.985 (0.881)–(1.101) 0.794

-mmHg/h[c] 45 140.8 (66.5–344.5) 45 145.7 (27.8–381.7)
AUC 6–24 h mmHg[c] [,] [f] 47 1954.8 (930.3–4045.5) 46 2326.7 (586.8–3911.5) 0.031 1.047 (0.986)–(1.111) 0.131 1.037 (0.963)–(1.116) 0.335

-mmHg/h[c] 47 108.6 (51.7–224.8) 46 129.3 (32.6–217.3)

Hypothermia[h]

Max. PaO2 > 200 mmHg[b] 22 14 (64%) 36 24 (67%) 1.00 1.143 (0.376)–(3.472) 0.814 0.435 (0.076)–(2.488) 0.349
Max. PaO2 > 250 mmHg[b] 22 14 (64%) 36 20 (56%) 0.593 0.714 (0.240)–(2.123) 0.545 0.218 (0.034)–(1.399) 0.108

Max. PaO2 > 300 mmHg[b] 22 12 (55%) 36 17 (47%) 0.787 0.746 (0.257)–(2.160) 0.589 0.398 (0.087)–(1.818) 0.235

AUC 0 – 24 h mmHg[c] [,] [f] 22 3264.8 (1682.5–5785.5) 35 3119.9 (565.9–4643.3) 0.159 0.945 (0.890)–(1.004) 0.069 0.916 (0.843)–(0.995) 0.038

-mmHg/h[c] 22 136.0 (70.1–241.1) 35 130.0 (23.6–193.5)
AUC 0–6 h mmHg[c] [,] [f] 19 1046.3 (297.8–1661.4) 33 867.5 (268.1–2221.8) 0.549 0.980 (0.861)–(1.117) 0.769 0.975 (0.839)–(1.133) 0.738

-mmHg/h[c] 19 174.4 (49.6–276.9) 33 144.6 (44.7–370.3)
AUC 6–24 h mmHg[c] [,] [f] 21 2278.1 (1384.3–4645.2) 35 2144.0 (424.4–3452.9) 0.110 0.923 (0.854)–(0.997) 0.041 0.882 (0.792)–(0.981) 0.021

-mmHg/h[c] 21 126.6 (76.9–258.1) 35 119.1 (23.6–191.8)

Abbreviations: AUC = area under the curve, max. = maximum, n = number, OR = odds ratio, PaO2 = partial pressure of arterial oxygen.

a Number of subjects in whom the variable was obtained.

b Number of subjects (%).

c Median (range).

d p-Value: independent sample t-test for continuous data or Mann–Whitney U test dependent on normality; Fisher’s exact test for dichotomous data.

e Adjusted for: age, gender, location of arrest, rhythm, basic life support/advanced pediatric life support, lowest pH, and highest lactate.

f Value was rescaled by dividing by 100 in advance of the regression analysis.

g Children without mild therapeutic hypothermia treatment or where the target temperature of 32–34 [◦]C was not reached.

h Children with mild therapeutic hypothermia treatment, where the target temperature of 32–34 [◦]C was reached.


-----

**Fig.** **3.** Observations of PaO2 for five selected patients in the dataset, cutoff versus area under the curve (AUC). (A) Low AUC value, no PaO2 above a cutoff value. (B) Low AUC
value, PaO2 above cutoff values. (C) High AUC value, no PaO2 above a cutoff value. (D) High AUC value, fluctuating PaO2 above cutoff values. (E) High AUC value, PaO2 above

cutoff values.


impairments in microcirculatory function during MTH, increased
amounts of dissolved oxygen could have maintained oxygen supply to the organs in the patients in the present study. Measurement
of systemic and cerebral tissue oxygenation by near-infrared spectroscopy, Laser–Doppler spectroscopy, functional imaging, and
perhaps even invasive methods, is necessary to study the interacting effects of hyperoxia and hypothermia on the outcome in
children after CA.
Another explanation could be the synergistic effect of hypothermia and hyperoxia. It has been demonstrated that hypothermia
attenuates oxidative stress after traumatic brain injury (TBI) in
children.[28] Hyperoxia has been shown to improve organ function,
and to attenuate tissue apoptosis and oxidative stress during early
septic shock.[29] Even anti-inflammatory effects of hyperoxia are
reported.[30]

Hyperoxia causes vasoconstriction. The mechanisms underlying this vasoconstriction are not well understood, but there are
different theories as mentioned by Sjoberg and Singer.[30]

4.4. Limitations

Several limitations of our study should be acknowledged. First,
this is an observational, retrospective, single-center cohort study
in a heterogeneous population without a control group over a relatively long study interval. Changes in clinical care during this study
period will have improved the outcome after CA; however this
probably did not change the impact of high oxygen levels on the
outcome, as the attention was more focused on preventing hypoxia,
rather than avoiding hyperoxia. Only recent international CA guidelines have recommended avoiding an arterial oxygen saturation of
100%.[17]

Another limitation is that the time intervals of PaO2 measurements were not standardized. We would recommend measuring
PaO2 at least every hour, which permits a more precise measurement of the AUC and thus a better estimation of the influence of
PaO2 on mortality.
A third limitation is the small number of patients in which MTH
was applied, as therapeutic hypothermia was introduced halfway
through the study period. However, this number of patients was not
smaller than that in other studies.[19,31] As our findings stem from
a small heterogeneous group of patients, we expect they will most

probably be confirmed by larger, homogeneous groups of patients.


A fourth limitation is that some important variables are lacking,
such as fluid administration during CPR, and time to ROSC.
Lastly, the information on temperature is limited. We recorded
the time in which MTH was reached, but we did not document
the course of the temperature during the following 24 h and during
rewarming. In addition, we did not document the presence of fever.

**5.** **Conclusions**

Aware of the limitations of our study, we would recommend
standardized prospective collection of all CA-related data in chil
dren in large multicenter networks. Retrospective analysis of a large

set of prospective collected data will help us to answer such difficult

questions in our very heterogeneous populations. Additionally, we
need to study the effects of PaO2 on physical outcome, neuropsychological outcome and health-related quality of life. Combining
this information will help us to achieve goal-directed therapy
which can automatically adjust the fraction of inspired oxygen to

the individual physical demands of a child. Until individualized
therapy can be practiced, we must use oxygen carefully within
the therapeutic window and avoid the harmful effects of extreme
values of PaO2.


**Financial** **support**

None.

**Conflict** **of** **interest** **statement**

None of the authors has declared a conflict of interest.

**Acknowledgments**

The authors thank Elsbeth de Jager for her help in data collection,

and Ko Hagoort for text editing.

**Appendix** **A.** **Supplementary** **data**


Supplementary data associated with this article can be

found, in the online version, at [http://dx.doi.org/10.1016/](http://dx.doi.org/10.1016/j.resuscitation.2014.12.013)
[j.resuscitation.2014.12.013.](http://dx.doi.org/10.1016/j.resuscitation.2014.12.013)


-----

**References**

1. [Donoghue](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0160) [AJ,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0160) [Nadkarni](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0160) [V,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0160) [Berg](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0160) [RA,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0160) [et](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0160) [al.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0160) [Out-of-hospital](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0160) [pediatric](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0160) [cardiac](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0160) [arrest:](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0160)
[an](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0160) [epidemiologic](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0160) [review](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0160) [and](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0160) [assessment](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0160) [of](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0160) [current](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0160) [knowledge.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0160) [Ann](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0160) [Emerg](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0160) [Med](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0160)
[2005;46:512–22.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0160)
2. [Tibballs](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0165) [J,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0165) [Kinney](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0165) [S.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0165) [A](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0165) [prospective](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0165) [study](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0165) [of](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0165) [outcome](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0165) [of](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0165) [in-patient](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0165) [paediatric](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0165)
[cardiopulmonary](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0165) [arrest.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0165) [Resuscitation](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0165) [2006;71:310–8.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0165)

3. [Meert](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0170) [KL,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0170) [Donaldson](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0170) [A,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0170) [Nadkarni](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0170) [V,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0170) [et](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0170) [al.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0170) [Multicenter](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0170) [cohort](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0170) [study](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0170) [of](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0170) [in-hospital](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0170)
[pediatric](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0170) [cardiac](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0170) [arrest.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0170) [Pediatr](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0170) [Crit](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0170) [Care](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0170) [Med](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0170) [2009;10:544–53.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0170)
4. [Moler](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0175) [FW,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0175) [Meert](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0175) [K,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0175) [Donaldson](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0175) [AE,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0175) [et](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0175) [al.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0175) [In-hospital](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0175) [versus](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0175) [out-of-hospital](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0175) [pedi-](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0175)
[atric](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0175) [cardiac](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0175) [arrest:](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0175) [a](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0175) [multicenter](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0175) [cohort](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0175) [study.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0175) [Crit](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0175) [Care](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0175) [Med](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0175) [2009;37:2259–67.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0175)
5. [Topjian](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0180) [AA,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0180) [Nadkarni](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0180) [VM,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0180) [Berg](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0180) [RA.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0180) [Cardiopulmonary](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0180) [resuscitation](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0180) [in](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0180) [children.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0180)
[Curr](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0180) [Opin](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0180) [Crit](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0180) [Care](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0180) [2009;15:203–8.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0180)
6. [Moler](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0185) [FW,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0185) [Donaldson](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0185) [AE,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0185) [Meert](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0185) [K,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0185) [et](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0185) [al.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0185) [Multicenter](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0185) [cohort](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0185) [study](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0185) [of](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0185) [out-of-](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0185)
[hospital](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0185) [pediatric](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0185) [cardiac](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0185) [arrest.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0185) [Crit](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0185) [Care](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0185) [Med](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0185) [2011;39:141–9.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0185)
7. [Becker](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0190) [LB.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0190) [New](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0190) [concepts](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0190) [in](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0190) [reactive](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0190) [oxygen](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0190) [species](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0190) [and](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0190) [cardiovascular](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0190) [reper-](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0190)
[fusion](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0190) [physiology.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0190) [Cardiovasc](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0190) [Res](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0190) [2004;61:461–70.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0190)
8. [Richards](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0195) [EM,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0195) [Fiskum](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0195) [G,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0195) [Rosenthal](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0195) [RE,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0195) [Hopkins](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0195) [I,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0195) [McKenna](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0195) [MC.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0195) [Hyperoxic](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0195) [reper-](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0195)
[fusion](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0195) [after](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0195) [global](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0195) [ischemia](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0195) [decreases](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0195) [hippocampal](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0195) [energy](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0195) [metabolism.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0195) [Stroke](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0195)
[2007;38:1578–84.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0195)
9. [Pilcher](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0200) [J,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0200) [Weatherall](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0200) [M,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0200) [Shirtcliffe](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0200) [P,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0200) [Bellomo](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0200) [R,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0200) [Young](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0200) [P,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0200) [Beasley](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0200) [R.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0200) [The](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0200) [effect](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0200)
[of](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0200) [hyperoxia](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0200) [following](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0200) [cardiac](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0200) [arrest](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0200) [–](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0200) [a](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0200) [systematic](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0200) [review](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0200) [and](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0200) [meta-analysis](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0200)
[of](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0200) [animal](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0200) [trials.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0200) [Resuscitation](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0200) [2012;83:417–22.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0200)
10. [Bellomo](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0205) [R,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0205) [Bailey](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0205) [M,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0205) [Eastwood](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0205) [GM,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0205) [et](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0205) [al.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0205) [Arterial](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0205) [hyperoxia](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0205) [and](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0205) [in-](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0205)
[hospital](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0205) [mortality](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0205) [after](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0205) [resuscitation](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0205) [from](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0205) [cardiac](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0205) [arrest.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0205) [Crit](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0205) [Care](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0205) [2011;15:](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0205)
[R90.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0205)
11. [Janz](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0210) [DR,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0210) [Hollenbeck](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0210) [RD,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0210) [Pollock](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0210) [JS,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0210) [McPherson](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0210) [JA,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0210) [Rice](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0210) [TW.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0210) [Hyperoxia](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0210) [is](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0210)
[associated](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0210) [with](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0210) [increased](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0210) [mortality](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0210) [in](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0210) [patients](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0210) [treated](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0210) [with](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0210) [mild](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0210) [thera-](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0210)
[peutic](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0210) [hypothermia](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0210) [after](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0210) [sudden](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0210) [cardiac](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0210) [arrest.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0210) [Crit](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0210) [Care](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0210) [Med](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0210) [2012;40:](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0210)
[3135–9.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0210)
12. [Kilgannon](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0215) [JH,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0215) [Jones](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0215) [AE,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0215) [Shapiro](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0215) [NI,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0215) [et](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0215) [al.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0215) [Association](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0215) [between](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0215) [arterial](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0215) [hyperoxia](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0215)
[following](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0215) [resuscitation](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0215) [from](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0215) [cardiac](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0215) [arrest](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0215) [in-hospital](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0215) [mortality.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0215) [J](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0215) [Am](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0215) [Med](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0215) [Assoc](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0215)
[2010;303:2165–71.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0215)
13. [Ferguson](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0220) [LP,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0220) [Durward](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0220) [A,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0220) [Tibby](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0220) [SM.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0220) [Relationship](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0220) [between](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0220) [arterial](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0220) [partial](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0220) [oxy-](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0220)

[gen](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0220) [pressure](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0220) [after](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0220) [resuscitation](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0220) [from](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0220) [cardiac](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0220) [arrest](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0220) [and](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0220) [mortality](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0220) [in](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0220) [children.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0220)

[Circulation](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0220) [2012;126:335–42.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0220)
14. [Del](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0225) [Castillo](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0225) [J,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0225) [Lopez-Herce](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0225) [J,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0225) [Matamoros](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0225) [M,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0225) [et](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0225) [al.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0225) [Hyperoxia,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0225) [hypocapnia](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0225) [and](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0225)
[hypercapnia](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0225) [as](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0225) [outcome](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0225) [factors](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0225) [after](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0225) [cardiac](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0225) [arrest](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0225) [in](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0225) [children.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0225) [Resuscitation](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0225)
[2012;83:1456–61.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0225)
15. [Bennett](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0230) [KS,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0230) [Clark](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0230) [AE,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0230) [Meert](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0230) [KL,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0230) [et](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0230) [al.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0230) [Early](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0230) [oxygenation](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0230) [and](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0230) [ventilation](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0230) [mea-](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0230)
[surements](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0230) [after](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0230) [pediatric](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0230) [cardiac](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0230) [arrest:](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0230) [lack](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0230) [of](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0230) [association](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0230) [with](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0230) [outcome.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0230) [Crit](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0230)
[Care](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0230) [Med](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0230) [2013;41:1534–42.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0230)


16. [Guerra-Wallace](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0235) [MM,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0235) [Casey](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0235) [3rd](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0235) [FL,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0235) [Bell](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0235) [MJ,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0235) [Fink](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0235) [EL,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0235) [Hickey](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0235) [RW.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0235) [Hyperoxia](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0235)
[and](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0235) [hypoxia](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0235) [in](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0235) [children](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0235) [resuscitated](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0235) [from](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0235) [cardiac](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0235) [arrest.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0235) [Pediatr](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0235) [Crit](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0235) [Care](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0235) [Med](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0235)
[2013;14:e143–8.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0235)
17. [Biarent](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0240) [D,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0240) [Bingham](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0240) [R,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0240) [Eich](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0240) [C,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0240) [et](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0240) [al.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0240) [European](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0240) [Resuscitation](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0240) [Council](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0240) [Guide-](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0240)
[lines](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0240) [for](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0240) [Resuscitation](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0240) [2010](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0240) [Section](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0240) [6.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0240) [Paediatric](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0240) [life](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0240) [support.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0240) [Resuscitation](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0240)
[2010;81:1364–88.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0240)
18. [Miller](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0245) [RD,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0245) [Afton-Bird](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0245) [G.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0245) [Miller](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0245) [anestesia.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0245) [Madrid:](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0245) [Elsevier;](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0245) [2005.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0245)
19. [Fink](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0250) [EL,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0250) [Clark](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0250) [RS,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0250) [Kochanek](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0250) [PM,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0250) [Bell](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0250) [MJ,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0250) [Watson](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0250) [RS.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0250) [A](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0250) [tertiary](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0250) [care](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0250) [center’s](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0250)
[experience](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0250) [with](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0250) [therapeutic](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0250) [hypothermia](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0250) [after](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0250) [pediatric](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0250) [cardiac](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0250) [arrest.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0250) [Pediatr](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0250)
[Crit](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0250) [Care](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0250) [Med](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0250) [2010;11:66–74.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0250)
20. [Topjian](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0255) [A,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0255) [Hutchins](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0255) [L,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0255) [DiLiberto](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0255) [MA,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0255) [et](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0255) [al.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0255) [Induction](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0255) [and](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0255) [maintenance](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0255) [of](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0255) [ther-](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0255)
[apeutic](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0255) [hypothermia](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0255) [after](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0255) [pediatric](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0255) [cardiac](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0255) [arrest:](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0255) [efficacy](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0255) [of](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0255) [a](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0255) [surface](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0255) [cooling](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0255)
[protocol.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0255) [Pediatr](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0255) [Crit](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0255) [Care](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0255) [Med](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0255) [2011;12:e127–35.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0255)

21. [Nielsen](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0260) [N,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0260) [Hovdenes](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0260) [J,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0260) [Nilsson](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0260) [F,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0260) [et](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0260) [al.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0260) [Outcome,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0260) [timing](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0260) [and](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0260) [adverse](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0260) [events](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0260) [in](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0260)
[therapeutic](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0260) [hypothermia](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0260) [after](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0260) [out-of-hospital](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0260) [cardiac](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0260) [arrest.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0260) [Acta](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0260) [Anaesthesiol](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0260)

[Scand](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0260) [2009;53:926–34.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0260)
22. [Nielsen](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0265) [N,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0265) [Wetterslev](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0265) [J,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0265) [Cronberg](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0265) [T,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0265) [et](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0265) [al.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0265) [Targeted](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0265) [temperature](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0265) [management](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0265) [at](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0265)
[33](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0265) [[◦]C](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0265) [versus](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0265) [36](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0265) [[◦]C](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0265) [after](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0265) [cardiac](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0265) [arrest.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0265) [N](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0265) [Engl](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0265) [J](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0265) [Med](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0265) [2013;369:2197–206.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0265)
23. [Che](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0270) [D,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0270) [Li](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0270) [L,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0270) [Kopil](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0270) [CM,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0270) [Liu](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0270) [Z,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0270) [Guo](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0270) [W,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0270) [Neumar](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0270) [RW.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0270) [Impact](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0270) [of](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0270) [therapeutic](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0270) [hypother-](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0270)
[mia](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0270) [onset](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0270) [and](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0270) [duration](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0270) [on](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0270) [survival,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0270) [neurologic](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0270) [function,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0270) [and](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0270) [neurodegeneration](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0270)
[after](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0270) [cardiac](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0270) [arrest.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0270) [Crit](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0270) [Care](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0270) [Med](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0270) [2011;39:1423–30.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0270)
24. [Tai](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0275) [MM.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0275) [A](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0275) [mathematical](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0275) [model](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0275) [for](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0275) [the](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0275) [determination](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0275) [of](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0275) [total](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0275) [area](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0275) [under](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0275) [glucose](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0275)
[tolerance](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0275) [and](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0275) [other](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0275) [metabolic](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0275) [curves.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0275) [Diabetes](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0275) [Care](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0275) [1994;17:152–4.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0275)
25. [Martin](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0280) [DS,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0280) [Grocott](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0280) [MP.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0280) [Oxygen](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0280) [therapy](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0280) [in](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0280) [critical](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0280) [illness:](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0280) [precise](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0280) [control](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0280) [of](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0280)
[arterial](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0280) [oxygenation](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0280) [and](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0280) [permissive](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0280) [hypoxemia.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0280) [Crit](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0280) [Care](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0280) [Med](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0280) [2013;41:423–32.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0280)
26. [van](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0285) [Genderen](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0285) [ME,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0285) [Lima](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0285) [A,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0285) [Akkerhuis](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0285) [M,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0285) [Bakker](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0285) [J,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0285) [van](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0285) [Bommel](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0285) [J.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0285) [Persistent](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0285)
[peripheral](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0285) [and](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0285) [microcirculatory](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0285) [perfusion](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0285) [alterations](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0285) [after](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0285) [out-of-hospital](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0285) [car-](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0285)
[diac](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0285) [arrest](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0285) [are](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0285) [associated](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0285) [with](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0285) [poor](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0285) [survival.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0285) [Crit](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0285) [Care](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0285) [Med](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0285) [2012;40:2287–94.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0285)
27. [Buijs](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0290) [EA,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0290) [Verboom](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0290) [EM,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0290) [Top](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0290) [AP,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0290) [et](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0290) [al.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0290) [Early](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0290) [microcirculatory](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0290) [impairment](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0290)
[during](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0290) [therapeutic](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0290) [hypothermia](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0290) [is](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0290) [associated](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0290) [with](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0290) [poor](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0290) [outcome](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0290) [in](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0290) [post-](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0290)
[cardiac](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0290) [arrest](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0290) [children:](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0290) [a](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0290) [prospective](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0290) [observational](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0290) [cohort](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0290) [study.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0290) [Resuscitation](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0290)
[2014;85:397–404.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0290)
28. [Bayir](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0295) [H,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0295) [Adelson](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0295) [PD,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0295) [Wisniewski](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0295) [SR,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0295) [et](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0295) [al.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0295) [Therapeutic](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0295) [hypothermia](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0295) [preserves](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0295)
[antioxidant](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0295) [defenses](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0295) [after](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0295) [severe](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0295) [traumatic](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0295) [brain](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0295) [injury](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0295) [in](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0295) [infants](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0295) [and](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0295) [children.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0295)
[Crit](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0295) [Care](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0295) [Med](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0295) [2009;37:689–95.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0295)
29. [Barth](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0300) [E,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0300) [Bassi](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0300) [G,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0300) [Maybauer](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0300) [DM,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0300) [et](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0300) [al.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0300) [Effects](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0300) [of](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0300) [ventilation](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0300) [with](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0300) [100%](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0300)
[oxygen](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0300) [during](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0300) [early](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0300) [hyperdynamic](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0300) [porcine](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0300) [fecal](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0300) [peritonitis.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0300) [Crit](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0300) [Care](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0300) [Med](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0300)
[2008;36:495–503.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0300)
30. [Sjoberg](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0305) [F,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0305) [Singer](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0305) [M.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0305) [The](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0305) [medical](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0305) [use](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0305) [of](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0305) [oxygen:](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0305) [a](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0305) [time](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0305) [for](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0305) [critical](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0305) [reappraisal.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0305) [J](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0305)
[Intern](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0305) [Med](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0305) [2013;274:505–28.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0305)
31. [Doherty](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0310) [DR,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0310) [Parshuram](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0310) [CS,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0310) [Gaboury](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0310) [I,](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0310) [et](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0310) [al.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0310) [Hypothermia](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0310) [therapy](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0310) [after](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0310) [pediatric](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0310)
[cardiac](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0310) [arrest.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0310) [Circulation](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0310) [2009;119:1492–500.](http://refhub.elsevier.com/S0300-9572(14)00897-1/sbref0310)


-----

